Participants in this study have diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma and must be at least 60 years old. Participants must also have received standard chemotherapy and their PET scans must show they had a complete response after chemotherapy.
This study is being done to see how well the study drug called Zevalin (ibritumomab tiuxetan) works and if it is safe to give. The study will compare the effects of the study drug with observation (no further therapy). Observation is standard care for cancer that is in complete remission. About 490 subjects with DLBCL from 80 sites worldwide will take part in this study.
Susan Gillen, 319-467-5827
Parents with children between the ages of 9 and 14 months are invited to participate in a research study conducted by researchers in the College of Dentistry and Department of Family Medicine at the University of Iowa. The purpose of this research study is to validate a questionnaire that can be used in a medical office setting to determine a child's risk of developing tooth decay. Compensation is provided. To learn more about the study, please call (866) 890-5963 or e-mail jeanette-daly@uiowa.edu.
call: (866) 890-5963
email: jeanette-daly@uiowa.edu
Non-Smoking males ages 18-45 with no respiratory problems are invited to participate in a research study. Study involves 2 visits, volunteers will be asked to undergo pulmonary function tests, CT scans andbronchoscopy Compensation provided. If interested please call 319-356-0578, please leave a voicemail if no answer or email Rebecca-beek@uiowa.edu.
call: 319-356-0578
email: rebecca-beek@uiowa.edu
Participants in this research study have been diagnosed with multiple myeloma or POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin changes, which is a syndrome in which patients have a plasma cell disease resembling multiple myeloma, and various organ changes). The purpose of this research study is to find out whether relapse or disease progression will be delayed when an autologous stem cell transplant (a transplant using your own stem cells) is combined with consolidation and maintenance treatment after transplant, and how safely this treatment can be given in patients with myeloma who are 65 years of age or older. All of the drugs that will be used are commercially available, are FDA approved for one or more cancers, and have been used in the treatment of multiple myeloma and/or other cancers. However, the drugs Doxorubicin, Etoposide, and Cisplatin are not FDA approved specifically for the treatment of multiple myeloma. Approximately 41 people will take part in this study conducted by investigators at the University of Iowa. This study will only be conducted at the University of Iowa.
Annick Tricot, 319-467-5830
Participants in this research study have been diagnosed with multiple myeloma or POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin changes, which is a syndrome in which patients have a plasma cell disease resembling multiple myeloma, and various organ changes). The purpose of this research study is to find out whether relapse or disease progression will be delayed when an autologous stem cell transplant (a transplant using patients' own stem cells) is combined with consolidation and maintenance treatment after transplant, and how safely this treatment can be given in patients with myeloma who are 65 years of age or older. All of the drugs that will be used are commercially available, are FDA approved for one or more cancers, and have been used in the treatment of multiple myeloma and/or other cancers. However, the drugs Doxorubicin, Etoposide, and Cisplatin are not FDA approved specifically for the treatment of multiple myeloma. Approximately 41 people will take part in this study conducted by investigators at the University of Iowa. This study will only be conducted at the University of Iowa.
Copyright © 2013 The University of Iowa. All Rights Reserved.